Over the last twenty years, a new phenotype, that occurs in the presence of both sarcopenia and obesity, defined as sarcopenic obesity. This term describes the coexistence of obesity, defined as the increase in body fat mass deposition, and sarcopenia, defined as the reduction in lean mass and muscle strength. This condition has been considered a scientific and clinical priority, as reported by the European Society for Clinical Nutrition and Metabolism (ESPEN) and the European Association for the Study of Obesity (EASO). Despite this fact, a lot of uncertainties still surround this condition. Namely, in terms of (i) definition, (ii) adverse short- and long-term health effects (i.e., medical disease, psychosocial functioning, quality of life and mortality) and (iii) clinical management. In fact, no consensus exists on a valid definition of sarcopenic obesity, its real effects on health outcomes and mortality, and optimum treatment strategies for this condition.
Therefore, we encourage investigators from different scientific backgrounds to submit to this Research Topic entitled "Understanding Sarcopenic Obesity: From Definition to Health Consequences and Management” that will accept manuscripts in the form of Original Research, Systematic Review, Review, Mini-Review, and Clinical Trial articles providing a platform for the presentation of recent advances in our knowledge on sarcopenic obesity. Ultimately, we aim to provide a deeper understanding and emphasis on crucial aspects of this condition in order to avoid bias and misinterpretations. In brief three important clinical questions (but not limited to) that need to be addressed are:
• What is the definition of sarcopenic obesity?
• Is sarcopenic obesity harmful to health?
• Is this condition worth treating?
Over the last twenty years, a new phenotype, that occurs in the presence of both sarcopenia and obesity, defined as sarcopenic obesity. This term describes the coexistence of obesity, defined as the increase in body fat mass deposition, and sarcopenia, defined as the reduction in lean mass and muscle strength. This condition has been considered a scientific and clinical priority, as reported by the European Society for Clinical Nutrition and Metabolism (ESPEN) and the European Association for the Study of Obesity (EASO). Despite this fact, a lot of uncertainties still surround this condition. Namely, in terms of (i) definition, (ii) adverse short- and long-term health effects (i.e., medical disease, psychosocial functioning, quality of life and mortality) and (iii) clinical management. In fact, no consensus exists on a valid definition of sarcopenic obesity, its real effects on health outcomes and mortality, and optimum treatment strategies for this condition.
Therefore, we encourage investigators from different scientific backgrounds to submit to this Research Topic entitled "Understanding Sarcopenic Obesity: From Definition to Health Consequences and Management” that will accept manuscripts in the form of Original Research, Systematic Review, Review, Mini-Review, and Clinical Trial articles providing a platform for the presentation of recent advances in our knowledge on sarcopenic obesity. Ultimately, we aim to provide a deeper understanding and emphasis on crucial aspects of this condition in order to avoid bias and misinterpretations. In brief three important clinical questions (but not limited to) that need to be addressed are:
• What is the definition of sarcopenic obesity?
• Is sarcopenic obesity harmful to health?
• Is this condition worth treating?
